LRK-4189

LRK-4189 is a targeted protein degrader (oral, daily) from Larkspur Biosciences. A first-in-class targeted protein degrader of PIP4K2C, a lipid kinase that cancer cells use to survive stress; the company says degrading it triggers cell death through loss of stress adaptations and metabolic failure. Its furthest stage is phase 1, for microsatellite stable colorectal cancer and solid tumours. ClinicalTrials.gov registers it in one study linked below. Dosing began (company news dated 2 Dec 2025); registry phase 1/2, recruiting. Whether it works in people has not been established unless a trial below reports it.